RMgmDB - Rodent Malaria genetically modified Parasites

Summary

RMgm-854
Malaria parasiteP. berghei
Genotype
DisruptedGene model (rodent): PBANKA_0923800; Gene model (P.falciparum): PF3D7_1124500; Gene product: pyruvate dehydrogenase E1 component subunit alpha (PDH E1α; PDH-E1)
Transgene
Transgene not Plasmodium: CDC perfringolysin O (PFO)
Promoter: Gene model: PBANKA_1003000; Gene model (P.falciparum): PF3D7_0405300; Gene product: liver specific protein 2, putative | sequestrin | 6-cysteine protein (LISP2)
3'UTR: Gene model: Not available; Gene product: Not available
Replacement locus: Gene model: PBANKA_0923800; Gene product: pyruvate dehydrogenase E1 component subunit alpha (PDH E1α; PDH-E1)
Transgene
Transgene not Plasmodium: GFP
Promoter: Gene model: PBANKA_1133300; Gene model (P.falciparum): PF3D7_1357100; Gene product: elongation factor 1-alpha (eef1a)
3'UTR: Gene model: PBANKA_0719300; Gene product: bifunctional dihydrofolate reductase-thymidylate synthase, putative (dhfr/ts)
Replacement locus: Gene model: PBANKA_0923800; Gene product: pyruvate dehydrogenase E1 component subunit alpha (PDH E1α; PDH-E1)
Phenotype Liver stage;
Last modified: 28 March 2013, 09:52
  *RMgm-854
Successful modificationThe parasite was generated by the genetic modification
The mutant contains the following genetic modification(s) Gene disruption, Introduction of a transgene, Introduction of a transgene
Reference (PubMed-PMID number) Reference 1 (PMID number) : 23500072
MR4 number
Parent parasite used to introduce the genetic modification
Rodent Malaria ParasiteP. berghei
Parent strain/lineP. berghei ANKA
Name parent line/clone Not applicable
Other information parent line
The mutant parasite was generated by
Name PI/ResearcherNagel A; Heussler V
Name Group/DepartmentInstitute of Cell Biology
Name InstituteUniversity of Bern
CityBern
CountrySwitzerland
Name of the mutant parasite
RMgm numberRMgm-854
Principal namePbΔPDH-E1-PFO(LS)
Alternative name
Standardized name
Is the mutant parasite cloned after genetic modificationYes
Phenotype
Asexual blood stageNot different from wild type
Gametocyte/GameteNot tested
Fertilization and ookineteNot tested
OocystNot different from wild type
SporozoiteNot different from wild type
Liver stageStrongly reduced infectivity of sporozoites. Only a very low number of mice developed blood stage parasitemia after infection with high numbers of sporozoites.
Maturing liver stages abort development as a result of a combination of the lack of expression of PDH-E1α and expression of FPO (see additional information)
Additional remarks phenotype

Mutant/mutation
The mutant lacks expression of PDH E1α (pyruvate dehydrogenase E1 alpha subunit ) and expresses (the toxin) CDC (cholesterol-dependent cytolysins) perfringolysin O (PFO) under the control of the liver stage-specific promoter of PBANKA_100300. FPO contains a C-terminal V5-tag. In addition, the mutant expresses GFP under the control of the constitutive eef1 promoter.

Protein (function)
Acetyl-CoA is synthesized from pyruvate by the enzyme complex pyruvate dehydrogenase (PDH). PDH is a member of the α-ketoacid dehydrogenase multienzyme complexes and consists of three subunits: pyruvate dehydrogenase (E1), dihydrolipoyl acetyltransferase (E2) and lipoamide dehydrogenase (dihydrolipoyl dehydrogenase; E3). Acetyl-CoA is an essential precursor of fatty acid synthesis in plastids and fuels the tricarboxylic acid (TCA) cycle in mitochondria, which generates energy in the form of ATP.
Analyses of P. yoelii and P. berghei mutants (RMgm-376, RMgm-677) lacking expression of PDH E1α (see below) indicate a non-essential role of PDH E1α for blood stages and mosquito stages but an important role during late liver stage development.

The CDC perfringolysin O (PFO) is a potent toxin that is expressed by the gram-positive bacterium, Clostridium perfringens (see Additional information). See also RMgm-853 for a mutant expressing FPO in maturing liver stages.

Phenotype
Strongly reduced infectivity of sporozoites. Only a very low number of mice developed blood stage parasitemia after infection with high numbers of sporozoites.
Injection of 5,000 PbΔPDH-E1-PFO(LS) sporozoites per mouse did not result in the development of a blood infection. Even when we used higher numbers (25,000 and 100,000) of sporozoites per mouse, only one of five mice in each group developed parasitemia and this with a long delay in patency.

Maturing liver stages abort development as a result of a combination of the lack of expression of PDH-E1α (see RMgm-677) and expression of FPO (see RMgm-853).

Evidence is presented for FPO expression in (the cytosol of) liver stages (evidence is presented for partial co-localisation with the PVM). Evidence is presented for premature rupture/damage of the PVM in maturing liver stages that express FPO (see RMgm-853).

Additional information
Pore-forming toxins are widespread in prokaryotes. Approximately one-third of all characterised bacterial toxins are PFPs. They are expressed as stable water-soluble monomers, which bind to their target membrane. The membrane binding is followed by a lateral diffusion and self-assembly with other PFP monomers, which leads to oligomerization to a so-called pre-pore complex. After further conformational changes, some parts of the pre-pore reach through the lipid bilayer to finally form a membrane-spanning pore. This, in turn, results in perforation of the target membrane. A huge group of PFPs consists of cholesterol-dependent  cytolysins (CDCs). As their name indicates, these proteins need cholesterol to become active. Cholesterol is a component of many membranes and is believed to function as a receptor for several CDCs and to trigger the conformational shift from the pre-pore to the pore form.
The CDC perfringolysin O (PFO) is a potent toxin that is expressed by the gram-positive bacterium, Clostridium perfringens. By oligomerization of up to 50 monomers, PFO forms pores with a final pore diameter between 30 and 45 nm. Although  PFO-membrane binding is maximal at pH 5.5–6, it also occurs at neutral pH. PFO is able to perforate different kinds of membranes such as phagosomal, vacuole and plasma membranes and it was expected to perforate the cholesterol-rich PV membrane (PVM) (Bano et al., 2007; Silvie et al., 2008) in P. berghei-infected hepatocytes.

At later stages of liver stage development (48 h p.i.), the PVM and the plasma membrane of mutant parasites were damaged because the GFP was no longer restricted to the parasite cytosol, but was distributed  throughout the host cell. In HepG2 cells infected with control parasites, GFP remained in the parasite at this stage of development.  Furthermore, in the mutant parasites, Exp1 distribution was clearly affected, again indicating  damage of the PVM. These results clearly show that the
expression of PFO leads to the expected premature rupture of the PVM, as well as the parasite plasma membrane. The parasites were able to express the putative cysteine protease, SERA2, a marker of late schizonts, confirming that the parasites can reach this stage before PVM rupture.
The premature PVM rupture had no direct negative effect on the host cell since the cell shape and motility, as well as contacts to neighbouring cells, were not affected.

Injection of 5,000 PbΔPDH-E1-PFO(LS) sporozoites per mouse did not result in the development of a blood infection. Even when we used higher numbers (25,000 and 100,000) of sporozoites per mouse, only one of five mice in each group developed parasitemia and this with a long delay in patency

Other mutants
RMgm-677: A P. berghei mutant lacking expression of PDH E1α (pyruvate dehydrogenase E1 alpha subunit ) .
See also RMgm-853 for a mutant expressing FPO in maturing liver stages.
 


  Disrupted: Mutant parasite with a disrupted gene
Details of the target gene
Gene Model of Rodent Parasite PBANKA_0923800
Gene Model P. falciparum ortholog PF3D7_1124500
Gene productpyruvate dehydrogenase E1 component subunit alpha
Gene product: Alternative namePDH E1α; PDH-E1
Details of the genetic modification
Inducable system usedNo
Additional remarks inducable system
Type of plasmid/construct usedPlasmid double cross-over
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Plasmid/construct sequence
Restriction sites to linearize plasmid
Partial or complete disruption of the geneComplete
Additional remarks partial/complete disruption
Selectable marker used to select the mutant parasitetgdhfr
Promoter of the selectable markerpbdhfr
Selection (positive) procedurepyrimethamine
Selection (negative) procedureNo
Additional remarks genetic modificationInitially the coding sequence of PFO (NCBI reference sequence: NP_561079.1; http://ncbi.nlm.nih.gov) was PCR-amplified from C. perfringens genomic DNA (gDNA) using the oligonucleotide primers 5-GCGGATCCATGATAAGATTTAAGAAAACAAAAT-3'and 5'-GCGCGGCCGCATTGTAAGTAATACTAGATCCAGG-3'. The PCR product was cloned via BamHI and NotI restriction sites into the pGFP103464 plasmid(Helm et al., 2010), (resulting plasmid: pL0017.1.4), a modified pL0017 plasmid version (pL0017; MR4 MRA-786) cloned in our laboratory. Additionally the original gfp sequence of the pL0017 plasmid was excised using BamHI and XbaI digestion and was replaced by a double-stranded (ds)DNA oligonucleotide (obtained by annealing the single-stranded (ss)DNA oligonucleotides 5'-GATCCGCGGCCGCCCTAGGAGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACGTAGT-3' and 5'-CTAGACTACGTAGAATCGAGACCGAGGAGAGGGTTAGGGATAGGCTTACCTCCTAGGGCGGCCGCG-3'), bearing the coding sequence for the V5-tag (bold letters) as well as a NotI restriction site, needed for the cloning of the pfo sequence.

For the generation of the PbΔPDH-E1-PFO(LS) P. berghei parasites, the full expression cassette for liver stage-specific PFO::V5 expression was cut out of pSI230-PFOLS plasmid DNA using EcoRI and ligated into the pdh-e1a knockout plasmid described in Deschermeier et al. (2012) (resulting plasmid: pPDH-E1a-KO-PFO(LS)). Genomic integration of this construct results in the replacement of a large part of the PbPDH-E1a open reading frame (ORF) with the PFO::V5- and
the GFP-expression cassettes as well as with a cassette mediating constitutive expression of the selection marker TgDHFR-TS.
Additional remarks selection procedure
Primer information: Primers used for amplification of the target sequences  Click to view information
Primer information: Primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Sequence Primer 3
Additional information primer 3
Sequence Primer 4
Additional information primer 4
Sequence Primer 5
Additional information primer 5
Sequence Primer 6
Additional information primer 6

  Transgene: Mutant parasite expressing a transgene
Type and details of transgene
Is the transgene Plasmodium derived Transgene: not Plasmodium
Transgene nameCDC perfringolysin O (PFO)
Details of the genetic modification
Inducable system usedNo
Additional remarks inducable system
Type of plasmid/constructPlasmid double cross-over
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Plasmid/construct sequence
Restriction sites to linearize plasmid
Selectable marker used to select the mutant parasitetgdhfr
Promoter of the selectable markerpbdhfr
Selection (positive) procedurepyrimethamine
Selection (negative) procedureNo
Additional remarks genetic modificationInitially the coding sequence of PFO (NCBI reference sequence: NP_561079.1; http://ncbi.nlm.nih.gov) was PCR-amplified from C. perfringens genomic DNA (gDNA) using the oligonucleotide primers 5-GCGGATCCATGATAAGATTTAAGAAAACAAAAT-3'and 5'-GCGCGGCCGCATTGTAAGTAATACTAGATCCAGG-3'. The PCR product was cloned via BamHI and NotI restriction sites into the pGFP103464 plasmid(Helm et al., 2010), (resulting plasmid: pL0017.1.4), a modified pL0017 plasmid version (pL0017; MR4 MRA-786) cloned in our laboratory. Additionally the original gfp sequence of the pL0017 plasmid was excised using BamHI and XbaI digestion and was replaced by a double-stranded (ds)DNA oligonucleotide (obtained by annealing the single-stranded (ss)DNA oligonucleotides 5'-GATCCGCGGCCGCCCTAGGAGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACGTAGT-3' and 5'-CTAGACTACGTAGAATCGAGACCGAGGAGAGGGTTAGGGATAGGCTTACCTCCTAGGGCGGCCGCG-3'), bearing the coding sequence for the V5-tag (bold letters) as well as a NotI restriction site, needed for the cloning of the pfo sequence.

For the generation of the PbΔPDH-E1-PFO(LS) P. berghei parasites, the full expression cassette for liver stage-specific PFO::V5 expression was cut out of pSI230-PFOLS plasmid DNA using EcoRI and ligated into the pdh-e1a knockout plasmid described in Deschermeier et al. (2012) (resulting plasmid: pPDH-E1a-KO-PFO(LS)). Genomic integration of this construct results in the replacement of a large part of the PbPDH-E1a open reading frame (ORF) with the PFO::V5- and
the GFP-expression cassettes as well as with a cassette mediating constitutive expression of the selection marker TgDHFR-TS.
Additional remarks selection procedure
Other details transgene
Promoter
Gene Model of Parasite PBANKA_1003000
Gene Model P. falciparum ortholog PF3D7_0405300
Gene productliver specific protein 2, putative | sequestrin | 6-cysteine protein
Gene product: Alternative nameLISP2
Primer information details of the primers used for amplification of the promoter sequence  Click to view information
Primer information details of the primers used for amplification of the promoter sequence  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
3'-UTR
Gene Model of Parasite Not available
Gene productNot available
Gene product: Alternative name
Primer information details of the primers used for amplification the 3'-UTR sequences  Click to view information
Primer information details of the primers used for amplification the 3'-UTR sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Insertion/Replacement locus
Replacement / InsertionReplacement locus
Gene Model of Parasite PBANKA_0923800
Gene productpyruvate dehydrogenase E1 component subunit alpha
Gene product: Alternative namePDH E1α; PDH-E1
Primer information details of the primers used for amplification of the target sequences  Click to view information
Primer information details of the primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Sequence Primer 3
Additional information primer 3
Sequence Primer 4
Additional information primer 4

  Transgene: Mutant parasite expressing a transgene
Type and details of transgene
Is the transgene Plasmodium derived Transgene: not Plasmodium
Transgene nameGFP
Details of the genetic modification
Inducable system usedNo
Additional remarks inducable system
Type of plasmid/constructPlasmid double cross-over
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Plasmid/construct sequence
Restriction sites to linearize plasmid
Selectable marker used to select the mutant parasitetgdhfr
Promoter of the selectable markerpbdhfr
Selection (positive) procedurepyrimethamine
Selection (negative) procedureNo
Additional remarks genetic modificationInitially the coding sequence of PFO (NCBI reference sequence: NP_561079.1; http://ncbi.nlm.nih.gov) was PCR-amplified from C. perfringens genomic DNA (gDNA) using the oligonucleotide primers 5-GCGGATCCATGATAAGATTTAAGAAAACAAAAT-3'and 5'-GCGCGGCCGCATTGTAAGTAATACTAGATCCAGG-3'. The PCR product was cloned via BamHI and NotI restriction sites into the pGFP103464 plasmid(Helm et al., 2010), (resulting plasmid: pL0017.1.4), a modified pL0017 plasmid version (pL0017; MR4 MRA-786) cloned in our laboratory. Additionally the original gfp sequence of the pL0017 plasmid was excised using BamHI and XbaI digestion and was replaced by a double-stranded (ds)DNA oligonucleotide (obtained by annealing the single-stranded (ss)DNA oligonucleotides 5'-GATCCGCGGCCGCCCTAGGAGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACGTAGT-3' and 5'-CTAGACTACGTAGAATCGAGACCGAGGAGAGGGTTAGGGATAGGCTTACCTCCTAGGGCGGCCGCG-3'), bearing the coding sequence for the V5-tag (bold letters) as well as a NotI restriction site, needed for the cloning of the pfo sequence.

For the generation of the PbΔPDH-E1-PFO(LS) P. berghei parasites, the full expression cassette for liver stage-specific PFO::V5 expression was cut out of pSI230-PFOLS plasmid DNA using EcoRI and ligated into the pdh-e1a knockout plasmid described in Deschermeier et al. (2012) (resulting plasmid: pPDH-E1a-KO-PFO(LS)). Genomic integration of this construct results in the replacement of a large part of the PbPDH-E1a open reading frame (ORF) with the PFO::V5- and
the GFP-expression cassettes as well as with a cassette mediating constitutive expression of the selection marker TgDHFR-TS.
Additional remarks selection procedure
Other details transgene
Promoter
Gene Model of Parasite PBANKA_1133300
Gene Model P. falciparum ortholog PF3D7_1357100
Gene productelongation factor 1-alpha
Gene product: Alternative nameeef1a
Primer information details of the primers used for amplification of the promoter sequence  Click to view information
Primer information details of the primers used for amplification of the promoter sequence  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
3'-UTR
Gene Model of Parasite PBANKA_0719300
Gene productbifunctional dihydrofolate reductase-thymidylate synthase, putative
Gene product: Alternative namedhfr/ts
Primer information details of the primers used for amplification the 3'-UTR sequences  Click to view information
Primer information details of the primers used for amplification the 3'-UTR sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Insertion/Replacement locus
Replacement / InsertionReplacement locus
Gene Model of Parasite PBANKA_0923800
Gene productpyruvate dehydrogenase E1 component subunit alpha
Gene product: Alternative namePDH E1α; PDH-E1
Primer information details of the primers used for amplification of the target sequences  Click to view information
Primer information details of the primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Sequence Primer 3
Additional information primer 3
Sequence Primer 4
Additional information primer 4